Efficacy of infliximab therapy for refractory pouchitis
Phase 1
Completed
- Conditions
- ulcerative colitis, pouchitis
- Registration Number
- JPRN-UMIN000013370
- Lead Sponsor
- Inflammatory bowel disease center, Hyogo college of medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with pre-existed malignancy, other infectious disease, heart failure, or infusion reaction for infliximab
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy of infliximab treatment will be assessed with pouchitis disease activity index before and after treatment
- Secondary Outcome Measures
Name Time Method Evaluate the association between dose of anti-TNF alpha before treatment and efficacy of treatment
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie infliximab's efficacy in refractory pouchitis patients with ulcerative colitis?
How does infliximab therapy compare to standard-of-care treatments for severe refractory pouchitis in clinical trials?
Which biomarkers correlate with response to anti-TNF therapy in ulcerative colitis-associated pouchitis?
What are the potential adverse events associated with infliximab treatment in post-colectomy pouchitis patients?
Are there combination therapies or alternative biologics showing promise for refractory pouchitis beyond infliximab?